About Neopharma

Since its founding in 2003, Neopharma has emerged as a global, technologically driven, and innovation-oriented company. Neopharma’s global presence is supported by 10 manufacturing facilities spread across 3 continents and regional offices in 50+ countries. Delivering branded and generic formulations and active pharmaceutical ingredients (APIs). Neopharma is one of the largest pharmaceutical companies in the MENA region with 100% subsidiaries in the USA, Japan, Brazil, the UK, and India. A vertically integrated business, comprising Key intermediaries, API, R&D, and Formulation facilities in regulated and emerging markets. The therapeutic segments covered are acute and chronic therapies and have a strong foot hold in the anti-infective segment. Neopharma is primarily focusing on novel therapeutics, increasing portfolio depth, and debilitating diseases at affordable prices.